Macrophage inflammatory protein 3α transgene attracts dendritic cells to established murine tumors and suppresses tumor growth

Journal of Clinical Investigation

Volumn 105, Issue 10, 2000, Pages 1383-1393

  Fushimi, Toshiaki ^a   Kojima, Akira ^a   Moore, Malcolm A S ^b   Crystal, Ronald G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CHEMOTAXIS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 0034111112     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI7548     Document Type: Article

References (71)

1. Banchereau, J., and Steinman, R.M. 1998. Dendritic cells and the control of immunity. Nature. 392:245-252.
2. Timmerman, J.M. 1999. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 50:507-529.
3. Rissoan, M.C., et al. 1999. Reciprocal control of T helper cell and dendritic cell differentiation. Science. 283:1183-1186.
4. Albert, M.L., Sauter, B., and Bhardwaj, N. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTL. Nature. 392:86-89.
5. Ashley, D.M., et al. 1997. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med. 186:1177-1182.
6. Boczkowski, D., Nair, S.K., Snyder, D., and Gilboa, E. 1996. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184:465-472.
7. Brossart, P., Goldrath, A.W., Burz, E.A., Martin, S., and Bevan, M.J. 1997. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J. Immunol. 158:3270-3276.
8. Celluzzi, C.M., Mayordomo, J.I., Storkus, W.J., Lotze, M.T., and Falo, L.D. 1996. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. 183:283-287.
9. Celluzzi, C.M., and Falo, L.D., Jr. 1998. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J. Immunol. 160:3081-3085.
10. Henderson, R.A., et al. 1996. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res. 56:3763-3770.
11. Hsu, F.J., et al. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52-58.
12. Mayordomo, J.I., et al. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1297-1302.
13. Mayordomo, J.I., et al. 1996. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183:1357-1365.
14. Nestle, F.O., et al. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328-332.
15. Paglia, P., Chiodoni, C., Rodolfo, M., and Colombo, M.P. 1996. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:317-322.
16. Porgador, A., Snyder, D., and Gilboa, E. 1996. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156:2918-2926.
17. Reeves, M.E., Royal, R.E., Lam, J.S., Rosenberg, S.A., and Hwu, P. 1996. Retroviral transduction of human dendritic cells with a tumor-b associated antigen gene. Cancer Res. 56:5672-5677.
18. Ribas, A., et al. 1997. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res. 57:2865-2869.
19. Schuler, G., Thurner, B., and Romani, N. 1997. Dendritic cells: from ignored cells to major players in T-cell-mediated immunity. Int. Arch. Allergy Immunol. 112:317-322.
20. Song, W., et al. 1997. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186:1247-1256.
21. Specht, J.M., et al. 1997. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186:1213-1221.
22. Wan, Y., Bramson, J., Carter, R., Graham, F., and Gauldie, J. 1997. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum. Gene Ther. 8:1355-1363.
23. Zitvogel, L., et al. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:87-97.
24. Bronte, V., et al. 1997. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc. Natl. Acad. Sci. USA. 94:3183-3188.
25. De Veerman, M., et al. 1999. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity. J. Immunol. 162:144-151.
26. Fields, R.C., Shimizu, K., and Mule, J.J. 1998. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 95:9482-9487.
27. Flamand, V., et al. 1994. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 24:605-610.
28. Gong, J., et al. 1998. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl. Acad. Sci. USA. 95:6279-6283.
29. Turing, T., De Leo, A.B., Lotze, M.T., and Storkus, W.J. 1997. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur. J. Immunol. 27:2702-2707.
30. Tuting, T., et al. 1998. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-α. J. Immunol. 160:1139-1147.
31. Wang, J., Saffold, S., Cao, X., Krauss, J., and Chen, W. 1998. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol 161:5516-5524.
32. Gong, J. 1997. Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells. Gene Ther. 4:1023-1028.
33. Gong, J., Chen, D., Kashiwaba, M., and Kufe, D. 1997. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3:558-561.
34. Cao, X., et al. 1998. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. J. Immunol. 161:6238-6244.
35. Hieshima, K., et al. 1997. Molecular cloning of a novel human CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver. Chemotactic activity for lymphocytes and gene localization on chromosome 2. J. Bio. Chem. 272:5846-5853.
36. Hromas, R., et al. 1997. Cloning and characterization of exodus, a novel β-chemokine. Blood. 89:3315-3322.
37. Power, C.A., et al. 1997. Cloning and characterization of a specific receptor for the novel CC chemokine MIP-3α from lung dendritic cells. J. Exp. Med. 186:825-835.
38. Rossi, D.L., Vicari, A.P., Franz-Bacon, K., McClanahan, T.K., and Zlotnik, A. 1997. Identification through bioinformatics of two new macrophage proinflammatory human chemokines: MIP-3α and MIP-3α. J. Immunol. 158:1033-1036.
39. Rosenfeld, M.A., et al. 1991. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science. 252:431-434.
40. Rosenfeld, M.A., et al. 1992. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell. 68:143-155.
41. Hersh, J., Crystal, R.G., and Bewig, B. 1995. Modulation of gene expression after replication-deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector. Gene Ther. 2:124-131.
42. Crystal, R.G., et al. 1994. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 8:42-51.
43. Wang, M., et al. 1995. Active immunotherapy of cancer with a non-replicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 154:4685-4692.
44. Rawle, F.C., et al. 1991. Specificity of the mouse cytotoxic T lymphocyte response to adenovirus 5. E1a is immunodominant in H-2b, but not in H-2d or H-2k mice. J. Immunol. 146:3977-3984.
45. Inaba, K., et al. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693-1702.
46. Falk, W., Goodwin, R.H.J., and Leonard, E.J. 1980. A 48-well micro chemotaxis assembly for rapid and accurate measurement of leukocyte migration. J. Immunol. Methods. 33:239-247.
47. Austyn, J.M., Kupiec-Weglinski, J.W., Hankins, D.F., and Morris, P.J. 1988. Migration patterns of dendritic cells in the mouse. Homing to T cell-dependent areas of spleen, and binding within marginal zone. J. Exp. Med. 167:646-651.
48. Kupiec-Weglinski, J.W., Austyn, J.M., and Morris, P.J. 1988. Migration patterns of dendritic cells in the mouse. Traffic from the blood, and T cell-dependent and -independent entry to lymphoid tissues. J. Exp. Med. 167:632-645.
49. Weinlich, G., et al. 1998. Entry into afferent lymphatics and maturation in situ of migrating murine cutaneous dendritic cells. J. Invest. Dermatol. 110:441-448.
50. Larsen, C.P., et al. 1990. Migration and maturation of Langerhans cells in skin transplants and explants. J. Exp. Med. 172:1483-1493.
51. Cumberbatch, M., and Kimber, I. 1995. Tumour necrosis factor-α is required for accumulation of dendritic cells in draining lymph nodes and for optimal contact sensitization. Immunology. 84:31-35.
52. Cumberbatch, M., Dearman, R.J., and Kimber, I. 1997. Langerhans cells require signals from both tumour necrosis factor-α and interleukin-1 β for migration. Immunology. 92:388-395.
53. Lee, C.T., et al. 1997. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum. Gene Ther. 8:187-193.
54. Roake, J.A., et al. 1995. Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J. Exp. Med. 181:2237-2247.
55. De Smedt, T., et al. 1996. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J. Exp. Med. 184:1413-1424.
56. Kaplan, G., et al. 1992. Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J. Exp. Med. 175:1717-1728.
57. MacPherson, G.G., Jenkins, C.D., Stein, M.J., and Edwards, C. 1995. Endotoxin-mediated dendritic cell release from the intestine. Characterization of released dendritic cells and TNF dependence. J. Immunol. 154:1317-1322.
58. Greaves, D.R., et al. 1997. CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3α and is highly expressed in human dendritic cells. J. Exp. Med. 186:837-844.
59. Morelli, A., Larregina, A., Chuluyan, I., Kolkowski, E., and Fainboim, L. 1996. Expression and modulation of C5a receptor (CD88) on skin dendritic cells. Chemotactic effect of C5a on skin migratory dendritic cells. Immunology. 89:126-134.
60. Sozzani, S., et al. 1995. Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines. J. Immunol. 155:3292-3295.
61. Sozzani, S., et al. 1997. Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J. Immunol. 159:1993-2000.
62. Godiska, R., et al. 1997. Human macrophage-denved chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J. Exp. Med. 185:1595-1604.
63. Xu, L.L., Warren, M.K., Rose, W.L., Gong, W., and Wang, J.M. 1996. Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro. J. Leukoc. Biol. 60:365-371.
64. Dieu, M.C., et al. 1998. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. 188:373-386.
65. Baba, M., et al. 1997. Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC. J. Biol. Chem. 272:14893-14898.
66. Liao, F., et al. 1997. STRL22 is a receptor for the CC chemokine MIP-3α. Biochem. Biophys. Res. Commun. 236:212-217.
67. Chen, K., et al. 1997. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res. 57:3511-3516.
68. Lynch, D.H., et al. 1997. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med. 3:625-631.
69. Maraskovsky, E., et al. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184:1953-1962.
70. Shurin, M.R., et al. 1997. FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol. 179:174-184.
71. Esche, C., Subbotin, V.M., Maliszewski, C., Lotze, M.T., and Shurin, M.R. 1998. FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res. 58:380-383.